Rosemont Pharmaceuticals are pleased to announce a strategic partnership deal with Kuwait-Saudi Pharmaceutical Industries Co (KSPICO)
The agreement was signed at the British Embassy in Kuwait by Mark Vallance, Rosemont Pharmaceuticals’ Head of International Sales and Rashed Khazal, Kuwait-Saudi Pharmaceutical Industries Co. (KSPICO) Chairman and Managing Director.
Through this partnership, KSPICO will license and distribute a range of Rosemont products in the Gulf Cooperation Council (GCC) and Middle East and North Africa (MENA) regions. The range includes oral liquid medicines to support patients with swallowing difficulties, and the healthcare professionals who care for them.
Rosemont Pharmaceuticals’ Head of International Sales, Mark Vallance, said, “International expansion is core to Rosemont’s strategic growth ambitions and this deal represents our first major multi-market/product partnership. We are delighted to be collaborating with KSPICO to collectively ensure more patients receive access to liquid medication across the MENA region”.
KSPICO’s Chairman and Managing Director Dr. Rashed Khazal said, “KSPICO has a solid track record and a unique market position, and it has the strong support of Kuwait’s government to carry out its mission of serving patients’ needs and continuously improving its technological capabilities. Introducing a diverse range of product lines produced by a global pharmaceutical leader like Rosemont Pharmaceuticals will enable us to expand our service to healthcare businesses not only locally, but also regionally across MENA.”
Rosemont look forward to working closely together with KSPICO to ensure the success of this strategic partnership.